的有关规定，会议合法有效。 二、会议审议情况 经与会监事审议并书面投票表决，逐项通过如下议案： 证券代码：300620 证券简称：光库科技 公告编号：2025-050 珠海光库科技股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 珠海光库科技股份有限公司（以下简称"公司"）第四届监事会第十一次会 议于 2025 年 8 月 11 日在公司会议室以现场结合通讯方式召开，本次应出席监事 舟先生主持，本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 等法律、法规以及《珠海光库科技股份有限公司章程》 （以下简称"《公司章程》"） （一） 审议通过《关于公司本次发行股份、可转换公司债券及支付现金购 买资产并募集配套资金暨关联交易符合相关法律法规规定条件的议案》 公司拟通过发行股份、可转换公司债券及支付现金的方式购买张关明、苏州 讯诺投资合伙企业（有限合伙）（以下简称"讯诺投资"）、刘晓明、杜文刚、 沙淑丽、于壮成合计 6 名交易对方合计持有的苏州安捷讯光电科技股份有限公司 （以下简称"标的公司"）的 100%股权（以下简称"本次交 ...

Overview of the Transaction - The company plans to acquire 51% equity of Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements [1][2] - The acquisition aims to enhance the company's industrial chain layout by leveraging Huize's technology and customer resources in drug research and clinical evaluation, which are highly synergistic with the company's existing biopharmaceutical business [2][10] - The agreement signed is a preliminary intention agreement and does not involve specific contract amounts; it is subject to further negotiation and due diligence [2][9] Parties Involved - The transferors include individuals and partnerships that do not have any related party relationships with the company and are not listed as dishonest executors [3][4][5] Target Company Information - Hunan Huize Biomedical Technology Co., Ltd. is a specialized CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services [5][6] - The company has established long-term partnerships with over 300 domestic and international pharmaceutical companies and research institutions, completing more than 1,000 technical service projects [6][10] Financial and Operational Aspects - The registered capital of Huize is approximately 11.1 million yuan, and it has been recognized as a national high-tech enterprise and a key "little giant" enterprise [5][6] - The main business includes drug wholesale and retail, clinical trial services, and various technical services related to medical research and development [5][6] Purpose and Impact of the Acquisition - The acquisition is expected to enhance the company's biopharmaceutical segment, improve profitability, and strengthen risk resistance [10] - It will also integrate clinical transformation research and drug development, leading to improved operational efficiency and significant synergies [10] - Overall, the transaction is aligned with the company's strategic development needs and aims to foster long-term sustainable growth [10]

Group 1 - The company held an emergency board meeting on August 11, 2025, to ensure efficient operations and timely information disclosure, with all seven directors present [1][2] - The board approved the termination of the asset acquisition plan involving the purchase of 96.9628% equity in Beijing Tianyi Enhua Technology Co., Ltd., due to a lack of consensus on core transaction terms after thorough negotiations [1][2] - The management has been authorized to handle all matters related to the termination of this transaction, effective from the date of the board's approval until the completion of the termination process [1]

Core Viewpoint - The company is facing a significant risk due to the upcoming auction of its major asset, the Shenzhen Huangting Plaza, which could lead to a substantial impact on its financial stability and operations [1] Group 1: Auction Details - The Shenzhen Intermediate Court will auction the company's wholly-owned subsidiary, Rongfa Investment's asset, the Shenzhen Huangting Plaza, on September 9-10, with a starting price of 3.053 billion yuan [1] - The auction includes the shopping center and related facilities and equipment [1] Group 2: Financial Impact - As of the end of 2024, the book value of Shenzhen Huangting Plaza is 5.75 billion yuan, accounting for 71.57% of the company's total assets [1] - The projected revenue from the Shenzhen Huangting Plaza for 2024 is 369 million yuan, representing 56.03% of the company's total revenue for the year [1] Group 3: Consequences of Auction - If the auction is successful, the company will lose ownership of a major asset, constituting a significant asset restructuring [1] - The loss of this key asset may lead to substantial effects on the company's assets, liabilities, and daily operations, potentially triggering financial warning signs for forced delisting [1]

Core Viewpoint - The company is facing a significant risk of losing its major asset, the Shenzhen Huangting Plaza, due to a court-ordered auction scheduled for September 9-10, 2025, with a starting price of 3.053 billion yuan [1] Group 1: Asset Auction Details - The Shenzhen Intermediate People's Court will auction the company's wholly-owned subsidiary, Rongfa Investment's asset, the Crystal Island Commercial Center (Shenzhen Huangting Plaza) [1] - The auction is set to take place on the JD.com judicial auction platform, with a starting price of 3.053 billion yuan [1] Group 2: Impact on Company - If the auction is successful, the company will lose ownership of the asset, constituting a major asset restructuring [1] - The auction outcome could significantly affect the company's assets, liabilities, and daily operations, potentially triggering financial warning signs under the Shenzhen Stock Exchange's listing rules [1] Group 3: Debt Resolution Efforts - The company is currently negotiating with creditors to reach a comprehensive settlement plan, including debt resolution [1] - Both parties are actively working towards an early resolution, which could lead to the court canceling the auction if an agreement is reached [1] - Successful implementation of the settlement plan may positively impact the company's future financial status and operations [1]

Core Viewpoint - The major asset restructuring of Haikong Group has faced significant delays and uncertainties, with no clear resolution in sight after more than three years of attempts [1][5][8]. Restructuring Progress - Haikong Group announced on August 8 that the completion of the restructuring remains uncertain, dependent on negotiations with the transaction party and other approvals [1][5]. - The restructuring plan has undergone three modifications, with the latest adjustment involving a shift from equity issuance to cash and/or asset payments, abandoning the fundraising component [7][8]. Financial Performance - Haikong Group has experienced continuous financial pressure, with a cumulative net loss of 569 million since 2020, and a projected loss of 26 to 32 million for the first half of 2025 [3][10][11]. - The company's asset-liability ratio reached 70.70% by the end of the first quarter of 2025, indicating significant financial strain [4][11]. Market Conditions - The performance of Haikong Group's target acquisition, Hainan Duty-Free, has not met expectations due to rapid changes in the duty-free market and increased competition [2][8]. - The traditional passenger transport sector, which is a core part of Haikong Group's business, has been shrinking, contributing to ongoing losses [3][11]. Historical Context - The restructuring process began in May 2022, with an initial valuation of Hainan Duty-Free at 5 billion yuan, which has since been revised down multiple times due to underperformance [6][10]. - The company's revenue has declined from approximately 1.3 billion yuan in 2012 to around 840 million yuan in 2024, reflecting a downward trend in its core operations [10].

Core Viewpoint - Binhai Energy (000695) is currently undergoing a major asset restructuring process, which is in the stages of due diligence, auditing, and evaluation, with further steps required for completion [1] Trading Information Summary - On August 8, 2025, Binhai Energy's stock closed at 11.86 yuan, down 0.42%, with a turnover rate of 1.85% and a trading volume of 41,100 shares, resulting in a transaction amount of 48.6953 million yuan [1] - On the same day, the net outflow of funds from major investors was 3.9355 million yuan, accounting for 8.08% of the total transaction amount; net outflow from speculative investors was 2.5624 million yuan, making up 5.26%; while retail investors saw a net inflow of 6.4979 million yuan, representing 13.34% of the total transaction amount [1]

Group 1: Major Asset Restructuring and Control Changes - Kaipu Cloud (688228) is planning a significant asset restructuring and will be suspended from trading starting August 11, 2025 [2] - Jiachuan Vision's control will change from Chen Kunjian to Mao Guangfu and Li Li, with the resumption of trading on August 11, 2025 [2][3] - Hangzhou High-tech's controlling shareholder will transfer 19.03% of shares to Beijing Jirong Weiye Energy Technology Co., Ltd. for a total of 495 million yuan [2][3] - Qidi Pharmaceutical's controlling shareholder will transfer 58,606,962 shares to Hunan Sailoxian, resulting in a change of control [3] Group 2: Companies Planning to List in Hong Kong - Wanxing Technology plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [4] - Puyuan Precision plans to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders [4] - Kefu Medical intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange, also considering existing shareholders' interests [4] Group 3: Investment and Acquisitions - Wantong Development is planning to invest 854.44 million yuan to acquire 62.98% of Shuduo Technology, which will become a subsidiary [5][6] - Shiyun Circuit plans to invest 125 million yuan in Shenzhen New Sound Semiconductor, acquiring 3.8238% of its shares [7] Group 4: Financial Performance Highlights - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a 35.58% increase year-on-year, with a net profit of 12.113 billion yuan, up 38.61% [9] - Yanjing Beer achieved a revenue of 8.558 billion yuan, a 6.37% increase, and a net profit of 1.103 billion yuan, up 45.45% [9] - Changqing Co. reported a revenue of 2.083 billion yuan, a 7.28% increase, and a net profit of 42.78 million yuan, up 117.75% [9] - Shuangyi Technology reported a revenue of 525 million yuan, a 44.57% increase, and a net profit of 99.87 million yuan, up 324.5% [9]

Group 1 - The core point of the article is that Tengjing Technology has decided to terminate the acquisition of 100% of Shenzhen Xuntech Communication Technology Co., Ltd. due to changes in the market environment and difficulties in reaching an agreement among the parties involved [1][3] - Tengjing Technology's actual controller's concerted actors reduced their holdings by nearly 90 million yuan during the period from the announcement of the acquisition to its termination [1][4] - The company stated that the termination of this major asset restructuring will not have a significant adverse impact on its existing production and operational activities or strategic development [1][3] Group 2 - Tengjing Technology initially announced on February 26 that it was planning to acquire control of Xuntech Communication through a combination of issuing shares and cash payments, but the transaction was still in the planning stage and lacked a formal agreement [2][3] - Xuntech Communication is a national high-tech enterprise specializing in the research, production, sales, and service of optical communication products, with a strong focus on high-density packaging technology and optical device integration technology [2] - Following the announcement of the acquisition intention, Tengjing Technology's stock price initially fell sharply but later rebounded [4] Group 3 - The share transfer plan involved a total of 2.587 million shares, accounting for 2.00% of Tengjing Technology's total share capital, with a transfer price set at 34.66 yuan per share [5][6] - The total amount from the share transfer by the concerted actors was approximately 89.665 million yuan [6]

Core Viewpoint - Tengjing Technology (688195) has decided to terminate its plan to acquire Shenzhen Xuntech Communication Technology Co., Ltd. and raise matching funds due to changes in the market environment and difficulties in reaching an agreement among the parties involved [2][3]. Group 1: Acquisition Details - In February, the company announced its intention to acquire control of Xuntech Communication through a combination of issuing shares and cash payments, which was expected to constitute a significant asset restructuring [2]. - The updated acquisition plan aimed to purchase 100% of Xuntech Communication's shares, but the latest announcement indicates that the transaction will not proceed [3]. - This acquisition was the first major asset restructuring since Tengjing Technology's listing in 2021 [4]. Group 2: Company Background - Xuntech Communication, established in 2008, is a national high-tech enterprise focused on the research and manufacturing of optical interconnection products, providing solutions for AI computing centers, cloud computing centers, 5G, and telecommunications networks [4]. - Tengjing Technology specializes in the research, production, and sales of various precision optical components and fiber optic devices, primarily serving the optical communication and fiber laser sectors [5]. Group 3: Financial Performance - Tengjing Technology's financial performance has been stable since its listing, with revenues of 303 million, 344 million, 340 million, and 446 million yuan from 2021 to 2024, and net profits of 52 million, 58 million, 41 million, and 70 million yuan during the same period [6]. - The company attributes its revenue growth in 2024 to a focus on optical and optoelectronic core businesses, optimization of business and product structures, and increased operational efficiency, while also capitalizing on the growing demand for high-speed optical communication components driven by AI computing [6].